Matt Angle, PhD is the Founder and CEO of Paradromics, a neurotechnology leader developing the world’s most advanced and clinically viable brain-computer interface (BCI) platform—bridging human thought and digital capability. He earned his PhD in Neuroscience from the University of Heidelberg, followed by postdoctoral research at Stanford University. Paradromics engineered its first clinical product, the Connexus® BCI, received two FDA Breakthrough Device Designations, and performed the first-in-human neural recording in May 2025. The company is now preparing to launch a clinical trial in early 2026, pending regulatory approval.